Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Manufacturing & supply

USFDA closes Dr. Reddy's Bachupally FTO-3 inspection with Voluntary Action Indicated status

Dr. Reddy's says the US regulator has classified its Hyderabad formulations plant inspection as VAI and considers the inspection officially closed.

16 Nov 2026 · Dr Reddys Laboratories Ltd RDY · Company news

Dr. Reddy's Laboratories has told Indian and US stock exchanges that the US Food and Drug Administration classified the GMP inspection of its FTO-3 formulations facility in Bachupally, Hyderabad, as Voluntary Action Indicated (VAI). The company made the disclosure on 14 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Dr Reddys Laboratories Ltd ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Manufacturing & supplyAll →